Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 514B 5.38B 4.61B 4.31B 3.95B 7.43B 7.55B 50.83B 19.9B 258B 20.19B 19.75B 852B P/E 2027 *
44.3x
P/E 2028 * 38.5x
Enterprise Value 514B 5.38B 4.61B 4.31B 3.95B 7.43B 7.55B 50.83B 19.9B 258B 20.19B 19.75B 852B EV / Sales 2027 *
12.1x
EV / Sales 2028 * 10.9x
Free-Float
-
Yield 2027 *
0.97%
Yield 2028 * 0.97%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day+5.39%
1 week+16.55%
Current month+14.20%
1 month+23.53%
3 months+26.89%
6 months+17.36%
Current year+22.59%
1 week 2,606.4
Extreme 2606.4
3,054.9
1 month 2,445.4
Extreme 2445.4
3,054.9
Current year 2,088.1
Extreme 2088.1
3,054.9
1 year 2,088.1
Extreme 2088.1
3,054.9
3 years 1,385.05
Extreme 1385.05
3,515.7
5 years 1,227
Extreme 1227
3,515.7
10 years 962.65
Extreme 962.65
3,515.7
Manager TitleAgeSince
Chief Executive Officer 56 2022-11-30
Director of Finance/CFO - 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-07-07
Director TitleAgeSince
Chairman 73 2019-03-31
Director/Board Member 59 2020-05-17
Director/Board Member 67 2022-05-15
Change 5-day change 1-year change 3-year change Capi.($)
+5.39%+16.55% - - 5.1B
+4.46%+4.92%+82.07%+132.77% 1,093B
+0.85%+4.81%+53.77%+63.38% 653B
+2.72%+6.92%+28.99%+77.12% 458B
+1.80%-0.41%+43.52%+44.05% 355B
+1.24%+1.00%+26.84%+42.21% 294B
+2.07%+1.74%+2.66%+13.06% 248B
+4.02%+6.29%+49.67%+69.68% 230B
+1.05%-2.52%-13.83%-52.13% 203B
+2.90%+8.63%+25.11%+94.36% 178B
Average +2.47%+1.20%+33.20%+53.83% 412.27B
Weighted average by Cap. +2.52%+1.45%+47.20%+74.18%

Financials

2027 *2028 *
Net sales 42.53B 445M 382M 356M 327M 615M 625M 4.21B 1.65B 21.33B 1.67B 1.63B 70.52B 47.17B 493M 423M 395M 363M 682M 693M 4.66B 1.83B 23.66B 1.85B 1.81B 78.21B
Net income 11.61B 121M 104M 97.3M 89.27M 168M 171M 1.15B 450M 5.82B 456M 446M 19.25B 13.36B 140M 120M 112M 103M 193M 196M 1.32B 517M 6.7B 525M 514M 22.16B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
26-08-19 3,032.40 +5.39% 1,374,693
26-08-18 ₹2,877.40 +6.46% 477,841
26-08-17 ₹2,702.90 +0.52% 84,337
26-08-14 ₹2,688.80 +0.79% 94,952
26-08-13 ₹2,667.70 +1.81% 59,367
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3,034.05INR
Average target price
3,081.00INR
Spread / Average Target
+1.55%

Quarterly revenue - Rate of surprise